income of $640,000 or $0.03 per basic and diluted share for the third quarter of 2013, an increase of 68% over the prior quarter and significantly improved over a net loss of $1.3 million, or $0.06 per share loss in the prior year. Revenue for the third quarter of 2013 was $14.5 million, increasing from $13.1 million in the preceding quarter and compared to $15.5 million for the third quarter of 2012. Adjusted EBITDA was $1.5 million, up from $848,000 in the previous quarter and an improvement of 43% compared to the third quarter of 2012.
I think we all know the answer to this question,,,,the real question is how large
the Post-Launch Gains will be.....I will venture to say they will be quite LARGE....
I know I should not watch the daily ups and downs in the SP because they are meaningless until there
are verifiable results from testing,, but it is difficult to look away,,,,,
Now, the most legitimate question in the mind of investors is what is the outlook of Galena as an investment? We believe that by acquiring the FDA approved Abstral and the market potential of NeuVax, the outlook for Galena is bright, and the company will outperform in the foreseeable future
car·pe di·em. noun \ˈkär-pe-ˈdē-ˌem, -ˈdī-, -əm\. Definition of CARPE DIEM. : the enjoyment of the pleasures of the moment without concern for the future ...
Additional disclosure: Fusion Research is a team of equity analysts. This article was written by Satya Prakash, one of our research analysts. We did not receive compensation for this article (other than from Seeking Alpha), and we have no business relationship with any company whose stock is mentioned in this article.
Galena experienced many positive developments in the past few quarters, including acquiring an FDA approved drug and advancement of its clinical trials. With the acquisition of Abstral, Galena will become a commercial organization. During the commercialization of Abstral, Galena will get a chance to build a relationship in the market that is beneficial for promoting its promising pipeline.
Now, the most legitimate question in the mind of investors is what is the outlook of Galena as an investment? We believe that by acquiring the FDA approved Abstral and the market potential of NeuVax, the outlook for Galena is bright, and the company will outperform in the foreseeable future.
If no news came from yesterdays conference, can we expect any news this morning?